Questcor Pharmaceuticals

Our Products

For questions, please contact Questcor customer service at 1.800.411.3065 Monday through Friday from 8 am until 4 pm Pacific Standard Time.

Questcor's working environment has allowed me to be successful by offering an excellent management team, realistic, attainable goals, and a competitive compensation plan.

— Doug D.

Regional Manager

This is a place where your ideas and opinions not only matter, but are encouraged. Truly unique, like no other company you will work for, a company with a very bright future.

— Matthew D.

Regional Manager

Working for a small company like Questcor allows you the opportunity to express and implement your own unique ideas. The company encourages professional growth without boundaries.

— Christine T.

Senior Acthar Specialist

Working at Questcor has been a rewarding growth opportunity both personally and professionally. Over the years and through many changes in the company, it has been a great experience to work with so many talented people who are focused on improving the lives of patients suffering from CNS and inflammatory disorders.

— Heather B.

Market Research

Hard work, teamwork, and a can-do spirit personify the people and the culture at Questcor.

— Todd B.

Regional Sales Manager

Our Products

We are committed and passionate about helping patients with serious, difficult-to-treat medical conditions.

At Questcor our patients are our top priority. Through our research and development initiatives we strive to better understand serious, difficult-to-treat medical conditions, as well as how our products can play a role in treating such conditions. By doing so we hope to help our patients live healthier, stronger, and more productive lives.

For more information on our two marketed products please click the links below.

H.P. Acthar^® Gel (repository corticotropin injection) is currently approved in the U.S. for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, as well as indicated for the treatment of several other diseases and disorders.

Doral^® (quazepam tablets, USP) is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.